148 related articles for article (PubMed ID: 24382184)
61. Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux.
Riganti C; Miraglia E; Viarisio D; Costamagna C; Pescarmona G; Ghigo D; Bosia A
Cancer Res; 2005 Jan; 65(2):516-25. PubMed ID: 15695394
[TBL] [Abstract][Full Text] [Related]
62. Reversal of doxorubicin resistance by the amiloride analogue EIPA in multidrug resistant human colon carcinoma cells.
Pannocchia A; Revelli S; Tamponi G; Giorgianni A; Todde R; Bosia A; Ghigo D
Cell Biochem Funct; 1996 Mar; 14(1):11-8. PubMed ID: 8907249
[TBL] [Abstract][Full Text] [Related]
63. Cytotoxicity of cinchona alkaloid organocatalysts against MES-SA and MES-SA/Dx5 multidrug-resistant uterine sarcoma cell lines.
Pósa SP; Dargó G; Nagy S; Kisszékelyi P; Garádi Z; Hámori L; Szakács G; Kupai J; Tóth S
Bioorg Med Chem; 2022 Aug; 67():116855. PubMed ID: 35640378
[TBL] [Abstract][Full Text] [Related]
64. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
[TBL] [Abstract][Full Text] [Related]
65. Tracers to monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals.
de Geus-Oei LF; van Eerd-Vismale J; Molthoff C; Corstens F; Oyen W; Boerman O
Cancer Biother Radiopharm; 2004 Aug; 19(4):457-65. PubMed ID: 15453960
[TBL] [Abstract][Full Text] [Related]
66. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells.
Lacayo NJ; Duran GE; Sikic BI
J Exp Ther Oncol; 2003; 3(3):127-35. PubMed ID: 14641819
[TBL] [Abstract][Full Text] [Related]
67. The Static Magnetic Field Remotely Boosts the Efficiency of Doxorubicin through Modulating ROS Behaviors.
Hajipour Verdom B; Abdolmaleki P; Behmanesh M
Sci Rep; 2018 Jan; 8(1):990. PubMed ID: 29343746
[TBL] [Abstract][Full Text] [Related]
68. Oleanolic and maslinic acid sensitize soft tissue sarcoma cells to doxorubicin by inhibiting the multidrug resistance protein MRP-1, but not P-glycoprotein.
Villar VH; Vögler O; Barceló F; Gómez-Florit M; Martínez-Serra J; Obrador-Hevia A; Martín-Broto J; Ruiz-Gutiérrez V; Alemany R
J Nutr Biochem; 2014 Apr; 25(4):429-38. PubMed ID: 24491315
[TBL] [Abstract][Full Text] [Related]
69. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells.
Wang J; Goh B; Lu W; Zhang Q; Chang A; Liu XY; Tan TM; Lee H
Biol Pharm Bull; 2005 May; 28(5):822-8. PubMed ID: 15863886
[TBL] [Abstract][Full Text] [Related]
70. Allopurinol, furosemide and a phytotherapeutic agent (Bazoton uno) reverse P-glycoprotein-mediated doxorubicin resistance in human uterine sarcoma MES-SA/Dx5 cells: a novel therapeutic perspective.
Angelini A; Centurione MA; Di Pietro R; Centurione L
J Biol Regul Homeost Agents; 2019 May-Jun,; 33(3):991-997. PubMed ID: 31162035
[No Abstract] [Full Text] [Related]
71. Pgp efflux pump decreases the cytostatic effect of CENP-E inhibitor GSK923295.
Tcherniuk SO; Oleinikov AV
Cancer Lett; 2015 May; 361(1):97-103. PubMed ID: 25725449
[TBL] [Abstract][Full Text] [Related]
72. Radioiodinated agents for imaging multidrug resistant tumors.
Kortylewicz ZP; Augustine AM; Nearman J; McGarry J; Baranowska-Kortylewicz J
Med Chem; 2009 Mar; 5(2):171-81. PubMed ID: 19275716
[TBL] [Abstract][Full Text] [Related]
73. Quercetin-POM (pivaloxymethyl) conjugates: Modulatory activity for P-glycoprotein-based multidrug resistance.
Kim MK; Park KS; Choo H; Chong Y
Phytomedicine; 2015 Jul; 22(7-8):778-85. PubMed ID: 26141765
[TBL] [Abstract][Full Text] [Related]
74. [Effect of decreased GSH on sensitivity of breast cancer cells to ADM].
Han XQ; Li ZH; Zhang JG; Jiang YD; Peng KJ; Wang LZ; Wang SR
Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 38(5):770-4. PubMed ID: 17953354
[TBL] [Abstract][Full Text] [Related]
75. Sensitization of drug resistant sarcoma tumors by membrane modulation via short chain sphingolipid-containing nanoparticles.
Zalba S; Seynhaeve ALB; Brouwers JF; Süss R; Verheij M; Ten Hagen TLM
Nanoscale; 2020 Aug; 12(32):16967-16979. PubMed ID: 32780078
[TBL] [Abstract][Full Text] [Related]
76. Photochemical internalization of therapeutic macromolecular agents: a novel strategy to kill multidrug-resistant cancer cells.
Selbo PK; Weyergang A; Bonsted A; Bown SG; Berg K
J Pharmacol Exp Ther; 2006 Nov; 319(2):604-12. PubMed ID: 16902053
[TBL] [Abstract][Full Text] [Related]
77. H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance.
Chegaev K; Rolando B; Cortese D; Gazzano E; Buondonno I; Lazzarato L; Fanelli M; Hattinger CM; Serra M; Riganti C; Fruttero R; Ghigo D; Gasco A
J Med Chem; 2016 May; 59(10):4881-9. PubMed ID: 27120394
[TBL] [Abstract][Full Text] [Related]
78. Overexpression of caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells.
Cai C; Chen J
Int J Cancer; 2004 Sep; 111(4):522-9. PubMed ID: 15239129
[TBL] [Abstract][Full Text] [Related]
79. Three-dimensional microenvironment confers enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy.
Gomes LR; Vessoni AT; Menck CF
Oncogene; 2015 Oct; 34(42):5329-40. PubMed ID: 25619836
[TBL] [Abstract][Full Text] [Related]
80. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein.
Schuurhuis GJ; Broxterman HJ; de Lange JH; Pinedo HM; van Heijningen TH; Kuiper CM; Scheffer GL; Scheper RJ; van Kalken CK; Baak JP
Br J Cancer; 1991 Nov; 64(5):857-61. PubMed ID: 1681887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
